

Characteristic	No. of Patients
<i>Gender</i>	
Female	17
Male	4
<i>EGFR activating mutation</i>	
L858R	4
Exon 19 deletion	14
G719X	2
Wild Type	1
<i>Clinical Response to erlotinib</i>	
Partial Response	16
Stable Disease	2
Not Evaluable	3
Drug Resistance Mechanism	
<i>EGFR T790M</i>	
Present	11
Absent	9
Not done	1
<i>MET amplification</i>	
Present	2
Absent	11
Not done	8
<i>MAPK1 amplification</i>	
Present	1
Absent	20
Not done	0

Table S1. Clinical and molecular characteristics of post-treatment tumor specimens from NSCLC patients treated with erlotinib.